Anti-VEGF therapies in the clinic
Open accessAbstract
The development and use of antiangiogenesis agents, particularly those targeting vascular endothelial growth factor (VEGF), has become an integral component of anticancer regimens for many tumor types. This review is intended to highlight some of the most important clinical successes and failures of anti-VEGF therapies, and where possible, to suggest important lessons that have been learned. This review emphasizes data from agents that have been FDA approved and/or have completed phase III studies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
VEGF pathway blockers, including neutralizing antibodies, soluble VEGFR hybrids, and VEGFR tyrosine kinase inhibitors, are used in the clinic typically with other targeted therapies.
“A wide variety of agents that block the VEGF signaling pathway, such as neutralizing antibodies to VEGFA or VEGFR, soluble VEGFR hybrids, or inhibitors of VEGFR’s tyrosine kinase domain, are currently used in the clinic, typically in combination with other targeted therapies [32].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [32]
The opening section describes VEGF-targeting agents as commonly used in the clinic and identifies approved bevacizumab and VEGFR-inhibiting drugs. But it says bevacizumab was generally approved with chemotherapy, while sunitinib, sorafenib, and pazopanib were approved as monotherapies—not that these agents are typically combined with other targeted therapies. The cited passages also do not establish soluble VEGFR hybrids as currently used in the clinic. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 145 · Cited by 237
Research works printed but not linked: 2
- [30]30. Foernzler D, Delmar P, Kockx M, Cassidy J, Saltz L, Scherer S. 2010. Tumor tissue based biomarker analysis in NO16966: A randomized phase III study of first-line bev- acizumab in combination with oxaliplatin-based chemo- therapy in patients with mCRC. 2010 Gastrointestinal Cancers Symposium Abstract 374. http://www.asco.org/ ASCOv2/Meetings/Abstracts?&vmview¼abst_detail_ view& confID¼72&abstractID¼2207.
- [116]116. Sanofi-Aventis. 2009. Phase 3 trial of aflibercept in meta- static pancreatic cancer discontinued. http://en.sanofi- aventis.com/press/press_releases/2009/ppc_26186.asp.
- Authors
- Meadows, K. L., & Hurwitz, H. I.
- Affiliations
- Duke Medical Center (US)
- ORCID
- Hurwitz, H. I.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-03-27
- Volume
- 2
- Issue
- 10
- Pages
- a006577-a006577
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3475399
- OpenAlex
- W2150654884
- Cited by
- 237
- References
- 145
- Citations by year
- 2026: 3 · 2025: 18 · 2024: 12 · 2023: 17 · 2022: 18 · 2021: 20 · 2020: 26 · 2019: 21 · 2018: 24 · 2017: 23 · 2016: 13 · 2015: 16 · 2014: 19 · 2013: 6 · 2012: 1
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- anti-VEGF therapy, vascular endothelial growth factor, angiogenesis inhibitors, cancer therapy, clinical trials, FDA-approved drugs, tumor angiogenesis
- MeSH terms
- Humans, Neoplasms, Neovascularization, Pathologic, Biomarkers, Tumor, Treatment Outcome, Drug Approval, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
